Global Antibody Therapeutics Market Size study, by Format (Antibody Fragment, Bispecific Antibody, Monoclonal Antibody, Polyclonal Antibody), by Route of Administration (Intravenous, Subcutaneous), by Source (Chimeric, Human, Humanized), by Disease Areas (Autoimmune & Inflammatory Diseases, Hematology, Immunology, Neurology, Oncology, Osteology), by End User (Hospitals, Long-term Care Facilities) and Regional Forecasts 2022-2032
The Global Antibody Therapeutics Market is valued approximately at USD 248.79 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 14.89% over the forecast period 2024-2032. Antibody therapeutics represent a class of medical treatments leveraging antibodies to enhance or mimic the immune system’s ability to combat diseases. With their high specificity and lower toxicity compared to conventional drugs, antibody therapeutics have emerged as effective treatments for a plethora of conditions, including cancers, autoimmune diseases, and infectious diseases. The growing prevalence of chronic diseases and increasing healthcare expenditure globally have significantly driven the adoption of antibody therapeutics. Despite these challenges, advancements in medical technology are leading to more efficient antibody production, and the emergence of next-generation antibodies along with supportive government initiatives for cancer care are anticipated to provide substantial opportunities for market growth.
The market dynamics are shaped by the significant utilization of monoclonal antibodies due to numerous regulatory approvals, and the growing use of antibody fragments for better tumour penetration and reduced immunogenicity. Bispecific antibodies, with their dual affinity, are also gaining traction for their diverse applications in cancer therapy. Furthermore, the intravenous route remains a common method for delivering antibody therapeutics, ensuring immediate bioavailability and rapid therapeutic action, whereas subcutaneous administration offers the convenience of self-administration and cost-effectiveness. However, the market faces challenges such as high development costs and complex regulatory approval processes, these factors anticipated to restrain market growth between 2024 and 2032.
Geographically, the market analysis covers key regions including North America, Europe, Asia Pacific, Latin America, and the Rest of the World. The North America leads the market driven by a well-established R&D ecosystem and high healthcare expenditure. North America, particularly the United States, boasts a highly advanced healthcare system with a strong focus on research and development. This infrastructure supports extensive clinical trials and facilitates the rapid adoption of new therapies. Various leading pharmaceutical and biotechnology companies, such as Amgen, Genentech (a subsidiary of Roche), and Johnson & Johnson, are based in North America. These companies invest heavily in the development and commercialization of antibody therapeutics. Furthermore, the Asia Pacific region is also anticipated to witness the fastest growth, driven by growing healthcare infrastructure and increased incidence of chronic diseases. Moreover, the European Union also plays a pivotal role in the antibody therapeutics landscape, with strong pharmaceutical industries and comprehensive intellectual property rights frameworks.
Major market players included in this report are:
AbbVie Inc.
AbCellera Biologics Inc.
Adaptimmune Therapeutics PLC
ADC Therapeutics SA
Aenova Holding GmbH
Almac Group Limited
Amgen Inc.
Antikor Biopharma
Argenx SE
Astellas Pharma Inc.
AstraZeneca PLC
Baxter International Inc.
Bayer AG
Becton, Dickinson and Company
Bio-Rad Laboratories, Inc.
The detailed segments and sub-segment of the market are explained below:
By Format:
Antibody Fragment
Bispecific Antibody
Monoclonal Antibody
Polyclonal Antibody
By Route of Administration:
Intravenous
Subcutaneous
By Source:
Chimeric
Human
Humanized
By Disease Areas:
Autoimmune & Inflammatory Diseases
Hematology
Immunology
Neurology
Oncology
Osteology
By End User:
Hospitals
Long-term Care Facilities
By Region:
North America:
U.S.
Canada
Europe:
UK
Germany
France
Spain
Italy
ROE
Asia Pacific:
China
India
Japan
Australia
South Korea
RoAPAC
Latin America:
Brazil
Mexico
Middle East & Africa:
Saudi Arabia
South Africa
RoMEA
Years considered for the study are as follows:
Historical year – 2022
Base year – 2023
Forecast period – 2024 to 2032
Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.
The market dynamics are shaped by the significant utilization of monoclonal antibodies due to numerous regulatory approvals, and the growing use of antibody fragments for better tumour penetration and reduced immunogenicity. Bispecific antibodies, with their dual affinity, are also gaining traction for their diverse applications in cancer therapy. Furthermore, the intravenous route remains a common method for delivering antibody therapeutics, ensuring immediate bioavailability and rapid therapeutic action, whereas subcutaneous administration offers the convenience of self-administration and cost-effectiveness. However, the market faces challenges such as high development costs and complex regulatory approval processes, these factors anticipated to restrain market growth between 2024 and 2032.
Geographically, the market analysis covers key regions including North America, Europe, Asia Pacific, Latin America, and the Rest of the World. The North America leads the market driven by a well-established R&D ecosystem and high healthcare expenditure. North America, particularly the United States, boasts a highly advanced healthcare system with a strong focus on research and development. This infrastructure supports extensive clinical trials and facilitates the rapid adoption of new therapies. Various leading pharmaceutical and biotechnology companies, such as Amgen, Genentech (a subsidiary of Roche), and Johnson & Johnson, are based in North America. These companies invest heavily in the development and commercialization of antibody therapeutics. Furthermore, the Asia Pacific region is also anticipated to witness the fastest growth, driven by growing healthcare infrastructure and increased incidence of chronic diseases. Moreover, the European Union also plays a pivotal role in the antibody therapeutics landscape, with strong pharmaceutical industries and comprehensive intellectual property rights frameworks.
Major market players included in this report are:
AbbVie Inc.
AbCellera Biologics Inc.
Adaptimmune Therapeutics PLC
ADC Therapeutics SA
Aenova Holding GmbH
Almac Group Limited
Amgen Inc.
Antikor Biopharma
Argenx SE
Astellas Pharma Inc.
AstraZeneca PLC
Baxter International Inc.
Bayer AG
Becton, Dickinson and Company
Bio-Rad Laboratories, Inc.
The detailed segments and sub-segment of the market are explained below:
By Format:
Antibody Fragment
Bispecific Antibody
Monoclonal Antibody
Polyclonal Antibody
By Route of Administration:
Intravenous
Subcutaneous
By Source:
Chimeric
Human
Humanized
By Disease Areas:
Autoimmune & Inflammatory Diseases
Hematology
Immunology
Neurology
Oncology
Osteology
By End User:
Hospitals
Long-term Care Facilities
By Region:
North America:
U.S.
Canada
Europe:
UK
Germany
France
Spain
Italy
ROE
Asia Pacific:
China
India
Japan
Australia
South Korea
RoAPAC
Latin America:
Brazil
Mexico
Middle East & Africa:
Saudi Arabia
South Africa
RoMEA
Years considered for the study are as follows:
Historical year – 2022
Base year – 2023
Forecast period – 2024 to 2032
Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.
CHAPTER 1. GLOBAL ANTIBODY THERAPEUTICS MARKET EXECUTIVE SUMMARY
1.1. Global Antibody Therapeutics Market Size & Forecast (2022- 2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Format
1.3.2. By Route of Administration
1.3.3. By Source
1.3.4. By Disease Areas
1.3.5. By End User
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion
CHAPTER 2. GLOBAL ANTIBODY THERAPEUTICS MARKET DEFINITION AND RESEARCH ASSUMPTIONS
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Consumer’s Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
CHAPTER 3. GLOBAL ANTIBODY THERAPEUTICS MARKET DYNAMICS
3.1. Market Drivers
3.1.1. Increasing Prevalence of Chronic Diseases
3.1.2. Advancements in Medical Technology
3.2. Market Challenges
3.2.1. High Development Costs
3.2.2. Complex Regulatory Approvals
3.3. Market Opportunities
3.3.1. Emergence of Next-Generation Antibodies
3.3.2. Supportive Government Initiatives for Cancer Care
CHAPTER 4. GLOBAL ANTIBODY THERAPEUTICS MARKET INDUSTRY ANALYSIS
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.1.7. Porter’s 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
CHAPTER 5. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE & FORECASTS BY FORMAT 2022-2032
5.1. Segment Dashboard
5.2. Global Antibody Therapeutics Market: Format Revenue Trend Analysis, 2022 & 2032 (USD Billion)
5.2.1. Antibody Fragment
5.2.2. Bispecific Antibody
5.2.3. Monoclonal Antibody
5.2.4. Polyclonal Antibody
CHAPTER 6. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE & FORECASTS BY ROUTE OF ADMINISTRATION 2022-2032
6.1. Segment Dashboard
6.2. Global Antibody Therapeutics Market: Route of Administration Revenue Trend Analysis, 2022 & 2032 (USD Billion)
6.2.1. Intravenous
6.2.2. Subcutaneous
CHAPTER 7. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE & FORECASTS BY SOURCE 2022-2032
7.1. Segment Dashboard
7.2. Global Antibody Therapeutics Market: Source Revenue Trend Analysis, 2022 & 2032 (USD Billion)
7.2.1. Chimeric
7.2.2. Human
7.2.3. Humanized
CHAPTER 8. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE & FORECASTS BY DISEASE AREAS 2022-2032
8.1. Segment Dashboard
8.2. Global Antibody Therapeutics Market: Disease Areas Revenue Trend Analysis, 2022 & 2032 (USD Billion)
8.2.1. Autoimmune & Inflammatory Diseases
8.2.2. Hematology
8.2.3. Immunology
8.2.4. Neurology
8.2.5. Oncology
8.2.6. Osteology
CHAPTER 9. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE & FORECASTS BY END USER 2022-2032
9.1. Segment Dashboard
9.2. Global Antibody Therapeutics Market: End User Revenue Trend Analysis, 2022 & 2032 (USD Billion)
9.2.1. Hospitals
9.2.2. Long-term Care Facilities
CHAPTER 10. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE & FORECASTS BY REGION 2022-2032
10.1. North America Antibody Therapeutics Market
10.1.1. U.S. Antibody Therapeutics Market
10.1.1.1. Format breakdown size & forecasts, 2022-2032
10.1.1.2. Route of Administration breakdown size & forecasts, 2022-2032
10.1.1.3. Source breakdown size & forecasts, 2022-2032
10.1.1.4. Disease Areas breakdown size & forecasts, 2022-2032
10.1.1.5. End User breakdown size & forecasts, 2022-2032
10.1.2. Canada Antibody Therapeutics Market
10.1.2.1. Format breakdown size & forecasts, 2022-2032
10.1.2.2. Route of Administration breakdown size & forecasts, 2022-2032
10.1.2.3. Source breakdown size & forecasts, 2022-2032
10.1.2.4. Disease Areas breakdown size & forecasts, 2022-2032
10.1.2.5. End User breakdown size & forecasts, 2022-2032
10.2. Europe Antibody Therapeutics Market
10.2.1. UK Antibody Therapeutics Market
10.2.1.1. Format breakdown size & forecasts, 2022-2032
10.2.1.2. Route of Administration breakdown size & forecasts, 2022-2032
10.2.1.3. Source breakdown size & forecasts, 2022-2032
10.2.1.4. Disease Areas breakdown size & forecasts, 2022-2032
10.2.1.5. End User breakdown size & forecasts, 2022-2032
10.2.2. Germany Antibody Therapeutics Market
10.2.2.1. Format breakdown size & forecasts, 2022-2032
10.2.2.2. Route of Administration breakdown size & forecasts, 2022-2032
10.2.2.3. Source breakdown size & forecasts, 2022-2032
10.2.2.4. Disease Areas breakdown size & forecasts, 2022-2032
10.2.2.5. End User breakdown size & forecasts, 2022-2032
10.2.3. France Antibody Therapeutics Market
10.2.3.1. Format breakdown size & forecasts, 2022-2032
10.2.3.2. Route of Administration breakdown size & forecasts, 2022-2032
10.2.3.3. Source breakdown size & forecasts, 2022-2032
10.2.3.4. Disease Areas breakdown size & forecasts, 2022-2032
10.2.3.5. End User breakdown size & forecasts, 2022-2032
10.2.4. Spain Antibody Therapeutics Market
10.2.4.1. Format breakdown size & forecasts, 2022-2032
10.2.4.2. Route of Administration breakdown size & forecasts, 2022-2032
10.2.4.3. Source breakdown size & forecasts, 2022-2032
10.2.4.4. Disease Areas breakdown size & forecasts, 2022-2032
10.2.4.5. End User breakdown size & forecasts, 2022-2032
10.2.5. Italy Antibody Therapeutics Market
10.2.5.1. Format breakdown size & forecasts, 2022-2032
10.2.5.2. Route of Administration breakdown size & forecasts, 2022-2032
10.2.5.3. Source breakdown size & forecasts, 2022-2032
10.2.5.4. Disease Areas breakdown size & forecasts, 2022-2032
10.2.5.5. End User breakdown size & forecasts, 2022-2032
10.2.6. Rest of Europe Antibody Therapeutics Market
10.2.6.1. Format breakdown size & forecasts, 2022-2032
10.2.6.2. Route of Administration breakdown size & forecasts, 2022-2032
10.2.6.3. Source breakdown size & forecasts, 2022-2032
10.2.6.4. Disease Areas breakdown size & forecasts, 2022-2032
10.2.6.5. End User breakdown size & forecasts, 2022-2032
10.3. Asia-Pacific Antibody Therapeutics Market
10.3.1. China Antibody Therapeutics Market
10.3.1.1. Format breakdown size & forecasts, 2022-2032
10.3.1.2. Route of Administration breakdown size & forecasts, 2022-2032
10.3.1.3. Source breakdown size & forecasts, 2022-2032
10.3.1.4. Disease Areas breakdown size & forecasts, 2022-2032
10.3.1.5. End User breakdown size & forecasts, 2022-2032
10.3.2. India Antibody Therapeutics Market
10.3.2.1. Format breakdown size & forecasts, 2022-2032
10.3.2.2. Route of Administration breakdown size & forecasts, 2022-2032
10.3.2.3. Source breakdown size & forecasts, 2022-2032
10.3.2.4. Disease Areas breakdown size & forecasts, 2022-2032
10.3.2.5. End User breakdown size & forecasts, 2022-2032
10.3.3. Japan Antibody Therapeutics Market
10.3.3.1. Format breakdown size & forecasts, 2022-2032
10.3.3.2. Route of Administration breakdown size & forecasts, 2022-2032
10.3.3.3. Source breakdown size & forecasts, 2022-2032
10.3.3.4. Disease Areas breakdown size & forecasts, 2022-2032
10.3.3.5. End User breakdown size & forecasts, 2022-2032
10.3.4. Australia Antibody Therapeutics Market
10.3.4.1. Format breakdown size & forecasts, 2022-2032
10.3.4.2. Route of Administration breakdown size & forecasts, 2022-2032
10.3.4.3. Source breakdown size & forecasts, 2022-2032
10.3.4.4. Disease Areas breakdown size & forecasts, 2022-2032
10.3.4.5. End User breakdown size & forecasts, 2022-2032
10.3.5. South Korea Antibody Therapeutics Market
10.3.5.1. Format breakdown size & forecasts, 2022-2032
10.3.5.2. Route of Administration breakdown size & forecasts, 2022-2032
10.3.5.3. Source breakdown size & forecasts, 2022-2032
10.3.5.4. Disease Areas breakdown size & forecasts, 2022-2032
10.3.5.5. End User breakdown size & forecasts, 2022-2032
10.3.6. Rest of Asia Pacific Antibody Therapeutics Market
10.3.6.1. Format breakdown size & forecasts, 2022-2032
10.3.6.2. Route of Administration breakdown size & forecasts, 2022-2032
10.3.6.3. Source breakdown size & forecasts, 2022-2032
10.3.6.4. Disease Areas breakdown size & forecasts, 2022-2032
10.3.6.5. End User breakdown size & forecasts, 2022-2032
10.4. Latin America Antibody Therapeutics Market
10.4.1. Brazil Antibody Therapeutics Market
10.4.1.1. Format breakdown size & forecasts, 2022-2032
10.4.1.2. Route of Administration breakdown size & forecasts, 2022-2032
10.4.1.3. Source breakdown size & forecasts, 2022-2032
10.4.1.4. Disease Areas breakdown size & forecasts, 2022-2032
10.4.1.5. End User breakdown size & forecasts, 2022-2032
10.4.2. Mexico Antibody Therapeutics Market
10.4.2.1. Format breakdown size & forecasts, 2022-2032
10.4.2.2. Route of Administration breakdown size & forecasts, 2022-2032
10.4.2.3. Source breakdown size & forecasts, 2022-2032
10.4.2.4. Disease Areas breakdown size & forecasts, 2022-2032
10.4.2.5. End User breakdown size & forecasts, 2022-2032
10.4.3. Rest of Latin America Antibody Therapeutics Market
10.4.3.1. Format breakdown size & forecasts, 2022-2032
10.4.3.2. Route of Administration breakdown size & forecasts, 2022-2032
10.4.3.3. Source breakdown size & forecasts, 2022-2032
10.4.3.4. Disease Areas breakdown size & forecasts, 2022-2032
10.4.3.5. End User breakdown size & forecasts, 2022-2032
10.5. Middle East & Africa Antibody Therapeutics Market
10.5.1. Saudi Arabia Antibody Therapeutics Market
10.5.1.1. Format breakdown size & forecasts, 2022-2032
10.5.1.2. Route of Administration breakdown size & forecasts, 2022-2032
10.5.1.3. Source breakdown size & forecasts, 2022-2032
10.5.1.4. Disease Areas breakdown size & forecasts, 2022-2032
10.5.1.5. End User breakdown size & forecasts, 2022-2032
10.5.2. South Africa Antibody Therapeutics Market
10.5.2.1. Format breakdown size & forecasts, 2022-2032
10.5.2.2. Route of Administration breakdown size & forecasts, 2022-2032
10.5.2.3. Source breakdown size & forecasts, 2022-2032
10.5.2.4. Disease Areas breakdown size & forecasts, 2022-2032
10.5.2.5. End User breakdown size & forecasts, 2022-2032
10.5.3. Rest of Middle East & Africa Antibody Therapeutics Market
10.5.3.1. Format breakdown size & forecasts, 2022-2032
10.5.3.2. Route of Administration breakdown size & forecasts, 2022-2032
10.5.3.3. Source breakdown size & forecasts, 2022-2032
10.5.3.4. Disease Areas breakdown size & forecasts, 2022-2032
10.5.3.5. End User breakdown size & forecasts, 2022-2032
CHAPTER 11. COMPETITIVE INTELLIGENCE
11.1. Key Company SWOT Analysis
11.1.1. AbbVie Inc.
11.1.2. AbCellera Biologics Inc.
11.1.3. Adaptimmune Therapeutics PLC.
11.2. Top Market Strategies
11.3. Company Profiles
11.3.1. AbbVie Inc.
11.3.1.1. Key Information
11.3.1.2. Overview
11.3.1.3. Financial (Subject to Data Availability)
11.3.1.4. Product Summary
11.3.1.5. Market Strategies
11.3.2. AbCellera Biologics Inc.
11.3.3. Adaptimmune Therapeutics PLC.
11.3.4. ADC Therapeutics SA
11.3.5. Aenova Holding GmbH
11.3.6. Almac Group Limited
11.3.7. Amgen Inc.
11.3.8. Antikor Biopharma
11.3.9. Argenx SE
11.3.10. Astellas Pharma Inc.
11.3.11. AstraZeneca PLC
11.3.12. Baxter International Inc.
11.3.13. Bayer AG
11.3.14. Becton, Dickinson and Company
11.3.15. Bio-Rad Laboratories, Inc.
CHAPTER 12. RESEARCH PROCESS
12.1. Research Process
12.1.1. Data Mining
12.1.2. Analysis
12.1.3. Market Estimation
12.1.4. Validation
12.1.5. Publishing
12.2. Research Attributes
1.1. Global Antibody Therapeutics Market Size & Forecast (2022- 2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Format
1.3.2. By Route of Administration
1.3.3. By Source
1.3.4. By Disease Areas
1.3.5. By End User
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion
CHAPTER 2. GLOBAL ANTIBODY THERAPEUTICS MARKET DEFINITION AND RESEARCH ASSUMPTIONS
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Consumer’s Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
CHAPTER 3. GLOBAL ANTIBODY THERAPEUTICS MARKET DYNAMICS
3.1. Market Drivers
3.1.1. Increasing Prevalence of Chronic Diseases
3.1.2. Advancements in Medical Technology
3.2. Market Challenges
3.2.1. High Development Costs
3.2.2. Complex Regulatory Approvals
3.3. Market Opportunities
3.3.1. Emergence of Next-Generation Antibodies
3.3.2. Supportive Government Initiatives for Cancer Care
CHAPTER 4. GLOBAL ANTIBODY THERAPEUTICS MARKET INDUSTRY ANALYSIS
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.1.7. Porter’s 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
CHAPTER 5. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE & FORECASTS BY FORMAT 2022-2032
5.1. Segment Dashboard
5.2. Global Antibody Therapeutics Market: Format Revenue Trend Analysis, 2022 & 2032 (USD Billion)
5.2.1. Antibody Fragment
5.2.2. Bispecific Antibody
5.2.3. Monoclonal Antibody
5.2.4. Polyclonal Antibody
CHAPTER 6. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE & FORECASTS BY ROUTE OF ADMINISTRATION 2022-2032
6.1. Segment Dashboard
6.2. Global Antibody Therapeutics Market: Route of Administration Revenue Trend Analysis, 2022 & 2032 (USD Billion)
6.2.1. Intravenous
6.2.2. Subcutaneous
CHAPTER 7. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE & FORECASTS BY SOURCE 2022-2032
7.1. Segment Dashboard
7.2. Global Antibody Therapeutics Market: Source Revenue Trend Analysis, 2022 & 2032 (USD Billion)
7.2.1. Chimeric
7.2.2. Human
7.2.3. Humanized
CHAPTER 8. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE & FORECASTS BY DISEASE AREAS 2022-2032
8.1. Segment Dashboard
8.2. Global Antibody Therapeutics Market: Disease Areas Revenue Trend Analysis, 2022 & 2032 (USD Billion)
8.2.1. Autoimmune & Inflammatory Diseases
8.2.2. Hematology
8.2.3. Immunology
8.2.4. Neurology
8.2.5. Oncology
8.2.6. Osteology
CHAPTER 9. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE & FORECASTS BY END USER 2022-2032
9.1. Segment Dashboard
9.2. Global Antibody Therapeutics Market: End User Revenue Trend Analysis, 2022 & 2032 (USD Billion)
9.2.1. Hospitals
9.2.2. Long-term Care Facilities
CHAPTER 10. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE & FORECASTS BY REGION 2022-2032
10.1. North America Antibody Therapeutics Market
10.1.1. U.S. Antibody Therapeutics Market
10.1.1.1. Format breakdown size & forecasts, 2022-2032
10.1.1.2. Route of Administration breakdown size & forecasts, 2022-2032
10.1.1.3. Source breakdown size & forecasts, 2022-2032
10.1.1.4. Disease Areas breakdown size & forecasts, 2022-2032
10.1.1.5. End User breakdown size & forecasts, 2022-2032
10.1.2. Canada Antibody Therapeutics Market
10.1.2.1. Format breakdown size & forecasts, 2022-2032
10.1.2.2. Route of Administration breakdown size & forecasts, 2022-2032
10.1.2.3. Source breakdown size & forecasts, 2022-2032
10.1.2.4. Disease Areas breakdown size & forecasts, 2022-2032
10.1.2.5. End User breakdown size & forecasts, 2022-2032
10.2. Europe Antibody Therapeutics Market
10.2.1. UK Antibody Therapeutics Market
10.2.1.1. Format breakdown size & forecasts, 2022-2032
10.2.1.2. Route of Administration breakdown size & forecasts, 2022-2032
10.2.1.3. Source breakdown size & forecasts, 2022-2032
10.2.1.4. Disease Areas breakdown size & forecasts, 2022-2032
10.2.1.5. End User breakdown size & forecasts, 2022-2032
10.2.2. Germany Antibody Therapeutics Market
10.2.2.1. Format breakdown size & forecasts, 2022-2032
10.2.2.2. Route of Administration breakdown size & forecasts, 2022-2032
10.2.2.3. Source breakdown size & forecasts, 2022-2032
10.2.2.4. Disease Areas breakdown size & forecasts, 2022-2032
10.2.2.5. End User breakdown size & forecasts, 2022-2032
10.2.3. France Antibody Therapeutics Market
10.2.3.1. Format breakdown size & forecasts, 2022-2032
10.2.3.2. Route of Administration breakdown size & forecasts, 2022-2032
10.2.3.3. Source breakdown size & forecasts, 2022-2032
10.2.3.4. Disease Areas breakdown size & forecasts, 2022-2032
10.2.3.5. End User breakdown size & forecasts, 2022-2032
10.2.4. Spain Antibody Therapeutics Market
10.2.4.1. Format breakdown size & forecasts, 2022-2032
10.2.4.2. Route of Administration breakdown size & forecasts, 2022-2032
10.2.4.3. Source breakdown size & forecasts, 2022-2032
10.2.4.4. Disease Areas breakdown size & forecasts, 2022-2032
10.2.4.5. End User breakdown size & forecasts, 2022-2032
10.2.5. Italy Antibody Therapeutics Market
10.2.5.1. Format breakdown size & forecasts, 2022-2032
10.2.5.2. Route of Administration breakdown size & forecasts, 2022-2032
10.2.5.3. Source breakdown size & forecasts, 2022-2032
10.2.5.4. Disease Areas breakdown size & forecasts, 2022-2032
10.2.5.5. End User breakdown size & forecasts, 2022-2032
10.2.6. Rest of Europe Antibody Therapeutics Market
10.2.6.1. Format breakdown size & forecasts, 2022-2032
10.2.6.2. Route of Administration breakdown size & forecasts, 2022-2032
10.2.6.3. Source breakdown size & forecasts, 2022-2032
10.2.6.4. Disease Areas breakdown size & forecasts, 2022-2032
10.2.6.5. End User breakdown size & forecasts, 2022-2032
10.3. Asia-Pacific Antibody Therapeutics Market
10.3.1. China Antibody Therapeutics Market
10.3.1.1. Format breakdown size & forecasts, 2022-2032
10.3.1.2. Route of Administration breakdown size & forecasts, 2022-2032
10.3.1.3. Source breakdown size & forecasts, 2022-2032
10.3.1.4. Disease Areas breakdown size & forecasts, 2022-2032
10.3.1.5. End User breakdown size & forecasts, 2022-2032
10.3.2. India Antibody Therapeutics Market
10.3.2.1. Format breakdown size & forecasts, 2022-2032
10.3.2.2. Route of Administration breakdown size & forecasts, 2022-2032
10.3.2.3. Source breakdown size & forecasts, 2022-2032
10.3.2.4. Disease Areas breakdown size & forecasts, 2022-2032
10.3.2.5. End User breakdown size & forecasts, 2022-2032
10.3.3. Japan Antibody Therapeutics Market
10.3.3.1. Format breakdown size & forecasts, 2022-2032
10.3.3.2. Route of Administration breakdown size & forecasts, 2022-2032
10.3.3.3. Source breakdown size & forecasts, 2022-2032
10.3.3.4. Disease Areas breakdown size & forecasts, 2022-2032
10.3.3.5. End User breakdown size & forecasts, 2022-2032
10.3.4. Australia Antibody Therapeutics Market
10.3.4.1. Format breakdown size & forecasts, 2022-2032
10.3.4.2. Route of Administration breakdown size & forecasts, 2022-2032
10.3.4.3. Source breakdown size & forecasts, 2022-2032
10.3.4.4. Disease Areas breakdown size & forecasts, 2022-2032
10.3.4.5. End User breakdown size & forecasts, 2022-2032
10.3.5. South Korea Antibody Therapeutics Market
10.3.5.1. Format breakdown size & forecasts, 2022-2032
10.3.5.2. Route of Administration breakdown size & forecasts, 2022-2032
10.3.5.3. Source breakdown size & forecasts, 2022-2032
10.3.5.4. Disease Areas breakdown size & forecasts, 2022-2032
10.3.5.5. End User breakdown size & forecasts, 2022-2032
10.3.6. Rest of Asia Pacific Antibody Therapeutics Market
10.3.6.1. Format breakdown size & forecasts, 2022-2032
10.3.6.2. Route of Administration breakdown size & forecasts, 2022-2032
10.3.6.3. Source breakdown size & forecasts, 2022-2032
10.3.6.4. Disease Areas breakdown size & forecasts, 2022-2032
10.3.6.5. End User breakdown size & forecasts, 2022-2032
10.4. Latin America Antibody Therapeutics Market
10.4.1. Brazil Antibody Therapeutics Market
10.4.1.1. Format breakdown size & forecasts, 2022-2032
10.4.1.2. Route of Administration breakdown size & forecasts, 2022-2032
10.4.1.3. Source breakdown size & forecasts, 2022-2032
10.4.1.4. Disease Areas breakdown size & forecasts, 2022-2032
10.4.1.5. End User breakdown size & forecasts, 2022-2032
10.4.2. Mexico Antibody Therapeutics Market
10.4.2.1. Format breakdown size & forecasts, 2022-2032
10.4.2.2. Route of Administration breakdown size & forecasts, 2022-2032
10.4.2.3. Source breakdown size & forecasts, 2022-2032
10.4.2.4. Disease Areas breakdown size & forecasts, 2022-2032
10.4.2.5. End User breakdown size & forecasts, 2022-2032
10.4.3. Rest of Latin America Antibody Therapeutics Market
10.4.3.1. Format breakdown size & forecasts, 2022-2032
10.4.3.2. Route of Administration breakdown size & forecasts, 2022-2032
10.4.3.3. Source breakdown size & forecasts, 2022-2032
10.4.3.4. Disease Areas breakdown size & forecasts, 2022-2032
10.4.3.5. End User breakdown size & forecasts, 2022-2032
10.5. Middle East & Africa Antibody Therapeutics Market
10.5.1. Saudi Arabia Antibody Therapeutics Market
10.5.1.1. Format breakdown size & forecasts, 2022-2032
10.5.1.2. Route of Administration breakdown size & forecasts, 2022-2032
10.5.1.3. Source breakdown size & forecasts, 2022-2032
10.5.1.4. Disease Areas breakdown size & forecasts, 2022-2032
10.5.1.5. End User breakdown size & forecasts, 2022-2032
10.5.2. South Africa Antibody Therapeutics Market
10.5.2.1. Format breakdown size & forecasts, 2022-2032
10.5.2.2. Route of Administration breakdown size & forecasts, 2022-2032
10.5.2.3. Source breakdown size & forecasts, 2022-2032
10.5.2.4. Disease Areas breakdown size & forecasts, 2022-2032
10.5.2.5. End User breakdown size & forecasts, 2022-2032
10.5.3. Rest of Middle East & Africa Antibody Therapeutics Market
10.5.3.1. Format breakdown size & forecasts, 2022-2032
10.5.3.2. Route of Administration breakdown size & forecasts, 2022-2032
10.5.3.3. Source breakdown size & forecasts, 2022-2032
10.5.3.4. Disease Areas breakdown size & forecasts, 2022-2032
10.5.3.5. End User breakdown size & forecasts, 2022-2032
CHAPTER 11. COMPETITIVE INTELLIGENCE
11.1. Key Company SWOT Analysis
11.1.1. AbbVie Inc.
11.1.2. AbCellera Biologics Inc.
11.1.3. Adaptimmune Therapeutics PLC.
11.2. Top Market Strategies
11.3. Company Profiles
11.3.1. AbbVie Inc.
11.3.1.1. Key Information
11.3.1.2. Overview
11.3.1.3. Financial (Subject to Data Availability)
11.3.1.4. Product Summary
11.3.1.5. Market Strategies
11.3.2. AbCellera Biologics Inc.
11.3.3. Adaptimmune Therapeutics PLC.
11.3.4. ADC Therapeutics SA
11.3.5. Aenova Holding GmbH
11.3.6. Almac Group Limited
11.3.7. Amgen Inc.
11.3.8. Antikor Biopharma
11.3.9. Argenx SE
11.3.10. Astellas Pharma Inc.
11.3.11. AstraZeneca PLC
11.3.12. Baxter International Inc.
11.3.13. Bayer AG
11.3.14. Becton, Dickinson and Company
11.3.15. Bio-Rad Laboratories, Inc.
CHAPTER 12. RESEARCH PROCESS
12.1. Research Process
12.1.1. Data Mining
12.1.2. Analysis
12.1.3. Market Estimation
12.1.4. Validation
12.1.5. Publishing
12.2. Research Attributes
LIST OF TABLES
TABLE 1. Global Antibody Therapeutics market, report scope
TABLE 2. Global Antibody Therapeutics market estimates & forecasts by Region 2022-2032 (USD Billion)
TABLE 3. Global Antibody Therapeutics market estimates & forecasts by Format 2022-2032 (USD Billion)
TABLE 4. Global Antibody Therapeutics market estimates & forecasts by Route of Administration 2022-2032 (USD Billion)
TABLE 5. Global Antibody Therapeutics market estimates & forecasts by Source 2022-2032 (USD Billion)
TABLE 6. Global Antibody Therapeutics market estimates & forecasts by Disease Areas 2022-2032 (USD Billion)
TABLE 7. Global Antibody Therapeutics market estimates & forecasts by End User 2022-2032 (USD Billion)
TABLE 8. Global Antibody Therapeutics market by segment, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 9. Global Antibody Therapeutics market by region, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 10. Global Antibody Therapeutics market by segment, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 11. Global Antibody Therapeutics market by region, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 12. Global Antibody Therapeutics market by segment, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 13. Global Antibody Therapeutics market by region, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 14. Global Antibody Therapeutics market by segment, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 15. U.S. Antibody Therapeutics market estimates & forecasts, 2022-2032 (USD Billion)
TABLE 16. U.S. Antibody Therapeutics market estimates & forecasts by segment 2022-2032 (USD Billion)
TABLE 17. U.S. Antibody Therapeutics market estimates & forecasts by segment 2022-2032 (USD Billion)
TABLE 18. Canada Antibody Therapeutics market estimates & forecasts, 2022-2032 (USD Billion)
TABLE 19. Canada Antibody Therapeutics market estimates & forecasts by segment 2022-2032 (USD Billion)
TABLE 20. Canada Antibody Therapeutics market estimates & forecasts by segment 2022-2032 (USD Billion)
TABLE 1. Global Antibody Therapeutics market, report scope
TABLE 2. Global Antibody Therapeutics market estimates & forecasts by Region 2022-2032 (USD Billion)
TABLE 3. Global Antibody Therapeutics market estimates & forecasts by Format 2022-2032 (USD Billion)
TABLE 4. Global Antibody Therapeutics market estimates & forecasts by Route of Administration 2022-2032 (USD Billion)
TABLE 5. Global Antibody Therapeutics market estimates & forecasts by Source 2022-2032 (USD Billion)
TABLE 6. Global Antibody Therapeutics market estimates & forecasts by Disease Areas 2022-2032 (USD Billion)
TABLE 7. Global Antibody Therapeutics market estimates & forecasts by End User 2022-2032 (USD Billion)
TABLE 8. Global Antibody Therapeutics market by segment, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 9. Global Antibody Therapeutics market by region, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 10. Global Antibody Therapeutics market by segment, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 11. Global Antibody Therapeutics market by region, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 12. Global Antibody Therapeutics market by segment, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 13. Global Antibody Therapeutics market by region, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 14. Global Antibody Therapeutics market by segment, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 15. U.S. Antibody Therapeutics market estimates & forecasts, 2022-2032 (USD Billion)
TABLE 16. U.S. Antibody Therapeutics market estimates & forecasts by segment 2022-2032 (USD Billion)
TABLE 17. U.S. Antibody Therapeutics market estimates & forecasts by segment 2022-2032 (USD Billion)
TABLE 18. Canada Antibody Therapeutics market estimates & forecasts, 2022-2032 (USD Billion)
TABLE 19. Canada Antibody Therapeutics market estimates & forecasts by segment 2022-2032 (USD Billion)
TABLE 20. Canada Antibody Therapeutics market estimates & forecasts by segment 2022-2032 (USD Billion)
LIST OF FIGURES
FIG 1. Global Antibody Therapeutics market, research methodology
FIG 2. Global Antibody Therapeutics market, market estimation techniques
FIG 3. Global market size estimates & forecast methods.
FIG 4. Global Antibody Therapeutics market, key trends 2023
FIG 5. Global Antibody Therapeutics market, growth prospects 2022-2032
FIG 6. Global Antibody Therapeutics market, porters 5 force model
FIG 7. Global Antibody Therapeutics market, PESTEL analysis
FIG 8. Global Antibody Therapeutics market, value chain analysis
FIG 9. Global Antibody Therapeutics market by segment, 2022 & 2032 (USD Billion)
FIG 10. Global Antibody Therapeutics market by segment, 2022 & 2032 (USD Billion)
FIG 11. Global Antibody Therapeutics market by segment, 2022 & 2032 (USD Billion)
FIG 12. Global Antibody Therapeutics market by segment, 2022 & 2032 (USD Billion)
FIG 13. Global Antibody Therapeutics market by segment, 2022 & 2032 (USD Billion)
FIG 14. Global Antibody Therapeutics market, regional snapshot 2022 & 2032
FIG 15. North America Antibody Therapeutics market 2022 & 2032 (USD Billion)
FIG 16. Europe Antibody Therapeutics market 2022 & 2032 (USD Billion)
FIG 17. Asia pacific Antibody Therapeutics market 2022 & 2032 (USD Billion)
FIG 18. Latin America Antibody Therapeutics market 2022 & 2032 (USD Billion)
FIG 19. Middle East & Africa Antibody Therapeutics market 2022 & 2032 (USD Billion)
FIG 20. Global Antibody Therapeutics market, company market share analysis (2023)
FIG 1. Global Antibody Therapeutics market, research methodology
FIG 2. Global Antibody Therapeutics market, market estimation techniques
FIG 3. Global market size estimates & forecast methods.
FIG 4. Global Antibody Therapeutics market, key trends 2023
FIG 5. Global Antibody Therapeutics market, growth prospects 2022-2032
FIG 6. Global Antibody Therapeutics market, porters 5 force model
FIG 7. Global Antibody Therapeutics market, PESTEL analysis
FIG 8. Global Antibody Therapeutics market, value chain analysis
FIG 9. Global Antibody Therapeutics market by segment, 2022 & 2032 (USD Billion)
FIG 10. Global Antibody Therapeutics market by segment, 2022 & 2032 (USD Billion)
FIG 11. Global Antibody Therapeutics market by segment, 2022 & 2032 (USD Billion)
FIG 12. Global Antibody Therapeutics market by segment, 2022 & 2032 (USD Billion)
FIG 13. Global Antibody Therapeutics market by segment, 2022 & 2032 (USD Billion)
FIG 14. Global Antibody Therapeutics market, regional snapshot 2022 & 2032
FIG 15. North America Antibody Therapeutics market 2022 & 2032 (USD Billion)
FIG 16. Europe Antibody Therapeutics market 2022 & 2032 (USD Billion)
FIG 17. Asia pacific Antibody Therapeutics market 2022 & 2032 (USD Billion)
FIG 18. Latin America Antibody Therapeutics market 2022 & 2032 (USD Billion)
FIG 19. Middle East & Africa Antibody Therapeutics market 2022 & 2032 (USD Billion)
FIG 20. Global Antibody Therapeutics market, company market share analysis (2023)
